Interview of CordenPharma Colorado's Brad DeHoff by Phenomenex

Apr 05, 2013
In a recent issue of their e-newslettter PrepLC eNews, the R&D staff at Phenomenex interviews Dr. Brad DeHoff, Director of R&D for CordenPharma Colorado, about current and future trends of the CMO industry.

With a PhD in Synthetic Organic Chemistry from the University of South Carolina and additional post-doctoral experience from the Université de Montréal, Dr. DeHoff began his career with Syntex more than 22 years ago as a Senior Chemist working in process research. Dr. DeHoff advanced to the level of Distinguished Scientist and assumed increasingly responsible assignments as Global Supply Leader for Fuzeon, Small Scale Production Manager, Technical Manager of Chemistry and Head of Development and Supply Projects before becoming R&D Director.

As the Director of R&D, Dr. DeHoff oversees a technical staff of approximately 35 organic chemists, analytical chemists, and process engineers with responsibility for CordenPharma Colorado’s process development, process optimization and process support activities.


Phenomenex:
Could you please explain the various preparative chromatography techniques that CordenPharma is able to offer its customers?


DeHoff and Staff:
Our expertise lies in reverse phase chromatography, but we also use ion exchange and normal phase chromatography at CordenPharma. Implementation of other techniques such as HILIC or embedded polar phases awaits a project requiring these techniques. CordenPharma Colorado has both high and low pressure systems for purification and concentration/capture steps at some of the largest scales available in the peptide industry.


Phenomenex:
In which technique do you see most interest and growth?


DeHoff and Staff:
At CordenPharma Colorado, large scale preparative reverse phase chromatography is the most requested technique. However, the ability to perform large scale chiral separations is an area that has been getting a lot of attention in the recent years.


Phenomenex:
Often chromatography is considered the "last resort" after all other purification approaches have failed. Which role does preparative chromatography play in your strategy planning when you start a new project?


DeHoff and Staff:
This is dependent on the type of target molecule that a customer has requested. If it is a peptide, then preparative chromatography is an integral part of the synthetic design, while in small molecule projects, crystallization for purification is the preferred strategy. At the end of the project analysis, the most cost effective strategy which yields high quality becomes the route of choice.


Phenomenex:
Presumably as a response to the economic recession some major pharmaceutical companies have closed some sites or labs with preparative chromatography capabilities for cost saving measures. Do you think that will lead to an increased outsourcing trend for chromatography services and how will this affect companies like CordenPharma? Is there a shortage of prep chromatography capacity available for outsourcing?


DeHoff and Staff:
This is an excellent observation. We have seen an increase in requests for prep chromatography services. CordenPharma Colorado believes there is a shortage of very large scale industrial purification capacity.

Click here for the full story.